Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study.
Jennifer MooiFiona ChionhPeter SavasJessica Da Gama DuarteGeoffrey ChongStephen BrownRachel WongTimothy J PriceAlysson WannEffie SkrinosJohn M MariadasonNiall C TebbuttPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
In a first-line mCRC population, the dual antiangiogenic combination, bevacizumab plus trebananib, without chemotherapy, was efficacious with durable responses. The toxicity profile of the combination was manageable and did not exceed that expected with bevacizumab +/- chemotherapy. Exploratory biomarker results raise the hypothesis that the antiangiogenic combination may enable the antitumor immune response in immunotolerant colorectal cancer.